COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #137 of 255
9/13 Early treatment study
Sulaiman et al., medRxiv, doi:10.1101/2020.09.09.20184143 (Preprint)
The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study
Source   PDF   Share   Tweet
Observational prospective 5,541 patients, adjusted HCQ mortality odds ratio OR 0.36, p = 0.012. Adjusted hospitalization OR 0.57, p < 0.001. Zinc supplementation was used in all cases. Early treatment in ambulatory fever clinics in Saudi Arabia.

Sulaiman et al., 9/13/2020, prospective, Saudi Arabia, Middle East, preprint, 22 authors, dosage 400mg bid day 1, 200mg bid days 2-5.
risk of death, 63.7% lower, RR 0.36, p = 0.01, treatment 7 of 1817 (0.4%), control 54 of 3724 (1.5%), adjusted per study, odds ratio converted to relative risk.
risk of hospitalization, 38.6% lower, RR 0.61, p = 0.001, treatment 171 of 1817 (9.4%), control 617 of 3724 (16.6%), adjusted per study, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 255 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit